June 4, 2008 - biOasis Technologies Inc. (the “Company”), (TSX.V: BTI) announces that it has been granted Patent # 2,230,372 by the Canadian Intellectual Property Office. “This is a significant and important patent for securing a large unmet need for a biomarker that can act as an aid to diagnosing and monitoring Alzheimer's disease and for identifying new therapeutics for Alzheimer's disease. The issuance of this patent follows double blind validation studies completed by unrelated groups of scientists, (Feldman et al; http://iospress.metapress.com/content/ryrmrkfwy9h5byh8 and Kim et al; http://www.nature.com/npp/journal/v25/n1/full/1395638a.html ) thereby validating this emerging biomarker under the strictest experimental design and conditions. The effectiveness of biomarker as an aid to diagnosing and monitoring Alzheimer's disease in bodily fluids is based on a noninvasive simply single immunoassay (blood test), to monitor the possible or probable appearance of the disease by measuring the biomarker on a yearly basis. Equally as significant, it may enable physicians to monitor the effectiveness of treatments and emerging therapeutics they are prescribing for their patients to combat the progression of this disease... biOasis Technologies' Press Release -
